Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
Ruben A. Mesa
Hematology/Oncology
Research output
:
Contribution to journal
›
Article
›
peer-review
6
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Myeloproliferative Disorders
100%
Imatinib Mesylate
87%
Pdgfra-Associated Chronic Eosinophilic Leukemia
80%
Protein-Tyrosine Kinases
69%
Leukemia, Myelomonocytic, Chronic
67%
Polycythemia Vera
59%
Primary Myelofibrosis
57%
Systemic Mastocytosis
45%
Essential Thrombocythemia
41%
Phosphotransferases
23%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
22%
Platelet-Derived Growth Factor alpha Receptor
21%
Dasatinib
21%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16%
Hematopoietic Stem Cells
15%
Phenotype
9%
Therapeutics
5%